A 2-part Phase 1/2 Open-label Trial on ODM-212
A phase 1/2 trial of Ipilimumab, Nivolumab, Gemcitabine in mesothelioma and non-small-cell lung cancer, run by Orion Corporation, Orion Pharma, now recruiting.
Overview
A 2-part Phase 1/2 Open-label Trial on ODM-212 is a phase 1/2 interventional study registered as NCT07563738 by Orion Corporation, Orion Pharma, with 229 participants planned, started 2026-03-27 and due to reach its primary completion in 2029-09. Interventions recorded: ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib. Conditions listed: Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Shares Ipilimumab, Mesothelioma, Nivolumab, Small-cell lung cancer.
- TrialA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre
Shares Ipilimumab, Paclitaxel / nab-paclitaxel, Nivolumab, Small-cell lung cancer.
- TrialPh I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAn Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Shares Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Shares Sotorasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Gemcitabine, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Gemcitabine, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi
Shares Sotorasib, Small-cell lung cancer, Non-small-cell lung cancer.